Paroxetine (Paxil) and CYP2D6 Pharmacogenomics

What Is Paroxetine?

Paroxetine (brand name Paxil) is a selective serotonin reuptake inhibitor (SSRI) prescribed for major depressive disorder, generalized anxiety disorder, social anxiety disorder, panic disorder, obsessive-compulsive disorder (OCD), and post-traumatic stress disorder (PTSD). It is one of the most commonly prescribed antidepressants worldwide.

What makes paroxetine uniquely important in pharmacogenomics is that, unlike most other SSRIs, it is primarily metabolized by CYP2D6 metabolism rather than the CYP2C19 enzyme. Paroxetine is also a potent inhibitor of CYP2D6, meaning it can affect the metabolism of other drugs that rely on this enzyme.

How CYP2D6 Affects Paroxetine Metabolism

After oral administration, paroxetine undergoes extensive first-pass metabolism, primarily through CYP2D6-mediated oxidation. CYP2D6 is responsible for the formation of the catechol intermediate, the major metabolic pathway for paroxetine clearance.

Because CYP2D6 is the primary clearance pathway, your CYP2D6 metabolizer status directly affects paroxetine plasma concentrations. Reduced CYP2D6 function leads to higher drug levels at the same dose; increased function leads to lower levels.

An important complicating factor is that paroxetine itself inhibits CYP2D6. With chronic dosing, paroxetine partially inhibits its own metabolism, which means the effect of CYP2D6 genotype on paroxetine levels can be somewhat attenuated over time. Despite this, CPIC has published specific guidelines because the initial exposure difference is still clinically relevant. Learn more about how pharmacogenomic testing works from raw DNA data.

Impact of CYP2D6 Metabolizer Status

Your CYP2D6 phenotype affects paroxetine exposure at standard doses:

• Ultrarapid Metabolizer (UM): Increased CYP2D6 activity may result in lower paroxetine plasma levels initially. Because paroxetine inhibits CYP2D6, this effect may partially diminish with chronic use. CPIC guidelines suggest considering an alternative SSRI or titrating upward under clinical monitoring.
• Normal Metabolizer (NM): Standard CYP2D6 function. Paroxetine is metabolized at the expected rate. Standard dosing applies.
• Intermediate Metabolizer (IM): Moderately reduced CYP2D6 activity. Paroxetine levels may be somewhat higher than expected. Standard starting dose is generally appropriate, but monitoring for side effects is advisable.
• Poor Metabolizer (PM): Significantly reduced or absent CYP2D6 activity. Paroxetine levels can be substantially elevated, increasing the risk of dose-dependent side effects. CPIC guidelines recommend selecting an alternative SSRI not predominantly metabolized by CYP2D6, or considering a dose reduction if paroxetine is used.

For a plain-language explanation of metabolizer categories, read our guide to metabolizer status.

CPIC Guideline Summary

The paroxetine–CYP2D6 interaction has a CPIC Level A classification — the strongest evidence level. The CPIC guideline for SSRIs and CYP2D6 (Hicks et al., 2015; PMID: 25974703) provides specific recommendations:

• NM: Initiate therapy at standard starting dose.
• IM: Initiate therapy at standard starting dose. Monitor for adverse effects.
• PM: Select an alternative SSRI not predominantly metabolized by CYP2D6 (e.g., escitalopram, sertraline). If paroxetine is used, consider a dose reduction with therapeutic monitoring. Dose adjustments are prescriber decisions based on the full clinical picture.
• UM: Consider an alternative SSRI not predominantly metabolized by CYP2D6. If paroxetine is continued, titrate dose upward with monitoring. All dose changes should be directed by the prescriber.

Paroxetine vs. Other SSRIs: The CYP2D6 vs. CYP2C19 Distinction

A key pharmacogenomic distinction among SSRIs is which enzyme primarily metabolizes the drug. Paroxetine and fluoxetine are primarily CYP2D6-dependent, while escitalopram, sertraline, and citalopram are primarily CYP2C19-dependent.

This means different pharmacogenes drive the dosing recommendations for different SSRIs. If your CYP2D6 status flags paroxetine, CYP2C19-dependent SSRIs may be alternatives — and vice versa. Your Psychiatric Medication Report covers both gene pathways, making it easier to see the full picture across SSRI options.

Understanding Your Results

If you have raw DNA data from 23andMe, AncestryDNA, or another consumer service, DecodeMyBio can analyze your CYP2D6 status and report whether paroxetine is flagged for your genotype. Your Psychiatric Medication Report will include your CYP2D6 diplotype, activity score, metabolizer phenotype, and the CPIC recommendation for paroxetine specifically.

Paroxetine response depends on many factors beyond CYP2D6 status, including other medications, liver function, age, and clinical indication. This report provides pharmacogenomic context that your prescriber can use alongside other clinical factors. See our methodology for how results are derived and our limitations page for important caveats.

When to Talk to Your Doctor

A pharmacogenomic report is not a substitute for clinical judgment. Discuss your CYP2D6 results with your prescriber if any of the following apply:

• You are starting paroxetine for the first time, or your prescriber is considering a dose change — your CYP2D6 status may inform the starting dose or titration strategy.
• You are experiencing side effects such as nausea, drowsiness, weight gain, or sexual dysfunction that may be related to elevated paroxetine levels.
• You are taking or considering tamoxifen — paroxetine is a potent CYP2D6 inhibitor and can significantly reduce tamoxifen activation. This combination requires careful clinical evaluation.
• You are taking other CYP2D6-dependent medications (such as codeine, atomoxetine, or aripiprazole) — paroxetine's CYP2D6 inhibition can alter their metabolism.
• You are pregnant, planning pregnancy, or breastfeeding — paroxetine has specific considerations in these contexts that require specialist guidance.

Never stop or change antidepressant therapy on your own. Abrupt discontinuation of paroxetine can cause significant withdrawal symptoms.

Important Limitations

Consumer pharmacogenomic analysis provides useful context but has important limitations:

• Phenoconversion: Your effective metabolizer status can differ from your genotype when other drugs inhibit or induce the same enzyme. This is called phenoconversion. Paroxetine is itself a potent CYP2D6 inhibitor — meaning it can convert a genotypic normal or ultrarapid metabolizer into a phenotypic poor metabolizer for other CYP2D6-dependent drugs. Conversely, other CYP2D6 inhibitors (such as fluoxetine or bupropion) can further elevate paroxetine levels. Your prescriber should account for all concomitant medications.
• Polypharmacy: Many psychiatric patients take multiple medications. Drug-drug interactions may alter paroxetine levels independently of genotype, and paroxetine's CYP2D6 inhibition can affect co-prescribed drugs.
• Comorbidities and organ function: Liver impairment, kidney disease, age, and body composition affect drug metabolism independently of genotype.
• Consumer array limitations: Genotyping arrays test many CYP2D6 SNP variants but cannot detect gene deletions (*5) or duplications that define some metabolizer phenotypes. For clinical-grade certainty, discuss CLIA-certified testing with your provider.
• Metabolism ≠ response: Pharmacogenomics shows how your body processes paroxetine, not whether it will effectively treat your condition. Antidepressant response involves neurobiology and clinical factors beyond drug metabolism.

For a detailed discussion, see our Limitations page.

Related Resources

• Pharmacogenomic Testing for Depression
• CYP2D6 and Antidepressants: Which Drugs Are Affected?
• CYP2C19 and SSRI Metabolism
• Venlafaxine (Effexor) and CYP2D6
• Amitriptyline (Elavil) — CYP2C19 + CYP2D6
• Aripiprazole (Abilify) and CYP2D6
• PRS vs. Pharmacogenomics — What's the Difference?
• Compare Pharmacogenomics Testing Options
• Pharmacogenomics From Raw DNA Data

Frequently Asked Questions

References

1. CPIC Guideline for SSRIs and CYP2D6 and CYP2C19. cpicpgx.org
2. PharmGKB Clinical Guideline Annotation: Paroxetine and CYP2D6. pharmgkb.org
3. PharmVar Gene Information: CYP2D6. pharmvar.org
4. FDA Table of Pharmacogenomic Biomarkers in Drug Labeling. fda.gov